Beam Therapeutics Inc. Financing Cash Flow
Beam Therapeutics Inc. (BEAM) reported Financing Cash Flow of $104.13 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-04
- Beam Therapeutics Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $7.52M, a 578.36% increase year-over-year.
- Beam Therapeutics Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $96.61M, a 79.59% decline year-over-year.
- Beam Therapeutics Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $1.89M, a 45.24% decline year-over-year.
- Beam Therapeutics Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $1.68M, a 32.73% increase year-over-year.
- Beam Therapeutics Inc. net cash provided by (used in) financing activities for fiscal 2025 was $478.05M, a 6079.54% increase from fiscal 2024.
- Beam Therapeutics Inc. net cash provided by (used in) financing activities for fiscal 2024 was $7.74M, a 97.20% decline from fiscal 2023.
- Beam Therapeutics Inc. net cash provided by (used in) financing activities for fiscal 2023 was $276.45M, a 147.74% increase from fiscal 2022.
- Beam Therapeutics Inc. net cash provided by (used in) financing activities for fiscal 2022 was $111.59M, a 85.24% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $104.13M 10-Q · filed 2026-08-04 | $106.02M derived: sum of 3 quarters · filed 2026-08-04 | $107.69M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $96.61M 10-Q · filed 2026-05-07 | $98.49M derived: sum of 2 quarters · filed 2026-05-07 | $100.17M derived: sum of 3 quarters · filed 2026-05-07 | $101.28M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $1.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $3.56M derived: sum of 2 quarters · filed 2026-02-24 | $4.67M derived: sum of 3 quarters · filed 2026-08-04 | $478.05M 10-K · filed 2026-02-24 |
| 2025-09-30 | $1.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $2.78M derived: sum of 2 quarters · filed 2026-08-04 | $476.16M 10-Q · filed 2025-11-04 | $479.61M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $1.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $474.49M 10-Q · filed 2026-08-04 | $477.93M derived: sum of 3 quarters · filed 2026-08-04 | $479.19M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $473.38M 10-Q · filed 2026-05-07 | $476.82M derived: sum of 2 quarters · filed 2026-05-07 | $478.08M derived: sum of 3 quarters · filed 2026-05-07 | $478.22M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $3.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $4.71M derived: sum of 2 quarters · filed 2026-02-24 | $4.84M derived: sum of 3 quarters · filed 2026-02-24 | $7.74M 10-K · filed 2026-02-24 |
| 2024-09-30 | $1.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $1.40M derived: sum of 2 quarters · filed 2025-11-04 | $4.29M 10-Q · filed 2025-11-04 | $38.01M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $133.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $3.03M 10-Q · filed 2025-08-05 | $36.74M derived: sum of 3 quarters · filed 2026-02-24 | $73.52M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $2.90M 10-Q · filed 2025-05-06 | $36.61M derived: sum of 2 quarters · filed 2026-02-24 | $73.39M derived: sum of 3 quarters · filed 2026-02-24 | $180.93M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $33.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $70.49M derived: sum of 2 quarters · filed 2026-02-24 | $178.03M derived: sum of 3 quarters · filed 2026-02-24 | $276.45M 10-K · filed 2026-02-24 |
| 2023-09-30 | $36.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $144.32M derived: sum of 2 quarters · filed 2024-11-05 | $242.74M 10-Q · filed 2024-11-05 | $274.75M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $107.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $205.96M 10-Q · filed 2024-08-06 | $237.97M derived: sum of 3 quarters · filed 2025-02-25 | $239.53M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $98.42M 10-Q · filed 2024-05-07 | $130.43M derived: sum of 2 quarters · filed 2025-02-25 | $131.99M derived: sum of 3 quarters · filed 2025-02-25 | $154.33M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $32.01M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $33.57M derived: sum of 2 quarters · filed 2025-02-25 | $55.91M derived: sum of 3 quarters · filed 2025-02-25 | $111.59M 10-K · filed 2025-02-25 |
| 2022-09-30 | $1.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $23.90M derived: sum of 2 quarters · filed 2023-11-08 | $79.58M 10-Q · filed 2023-11-08 | $101.12M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $22.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $78.02M 10-Q · filed 2023-08-08 | $99.56M derived: sum of 3 quarters · filed 2024-02-27 | $420.44M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $55.68M 10-Q · filed 2023-05-10 | $77.22M derived: sum of 2 quarters · filed 2024-02-27 | $398.11M derived: sum of 3 quarters · filed 2024-02-27 | $558.54M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $21.54M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $342.43M derived: sum of 2 quarters · filed 2024-02-27 | $502.87M derived: sum of 3 quarters · filed 2024-02-27 | $756.14M 10-K · filed 2024-02-27 |
| 2021-09-30 | $320.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $481.32M derived: sum of 2 quarters · filed 2022-11-07 | $734.60M 10-Q · filed 2022-11-07 | $864.59M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $160.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $413.71M 10-Q · filed 2022-08-09 | $543.71M derived: sum of 3 quarters · filed 2023-02-28 | $543.80M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $253.27M 10-Q · filed 2022-05-09 | $383.27M derived: sum of 2 quarters · filed 2023-02-28 | $383.36M derived: sum of 3 quarters · filed 2023-02-28 | $382.58M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $129.99M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $130.09M derived: sum of 2 quarters · filed 2023-02-28 | $129.31M derived: sum of 3 quarters · filed 2023-02-28 | $322.32M 10-K · filed 2023-02-28 |
| 2020-09-30 | $94.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | -$685.00K derived: sum of 2 quarters · filed 2021-11-08 | $192.33M 10-Q · filed 2021-11-08 | $193.03M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$779.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $192.24M 10-Q · filed 2021-08-10 | $192.93M derived: sum of 3 quarters · filed 2022-02-28 | $195.63M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $193.01M 10-Q · filed 2021-05-11 | $193.71M derived: sum of 2 quarters · filed 2022-02-28 | $196.41M derived: sum of 3 quarters · filed 2022-02-28 | $196.38M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $699.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $3.39M derived: sum of 2 quarters · filed 2022-02-28 | $3.37M derived: sum of 3 quarters · filed 2022-02-28 | $41.28M 10-K · filed 2022-02-28 |
| 2019-09-30 | $2.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $2.67M derived: sum of 2 quarters · filed 2020-11-10 | $40.58M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | -$20.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | $37.89M 10-Q · filed 2020-08-12 | ||
| 2019-03-31 | $37.91M 10-Q · filed 2020-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |